Record FY17 for Singapore Medical Group with FY18 expected to be stronger

SINGAPORE (Mar 2): RHB is maintaining its “buy” call on Singapore Medical Group (SMG) with a target price of 68 cents, as the group’s turnaround is further validated by organic and inorganic growth.

This came on the back of the group announcing that its FY17 earnings surged 250.8% to a record $8.5 million from $2.42 million in FY16.